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Increasing evidence indicates that blood platelets contribute to diverse processes that extend beyond hemostasis. Many of the same 
mechanisms that play a role in hemostasis and thrombosis facilitate platelets the participation in other physiological and pathological 
processes, particularly in the inflammation, the immune response and central nervous system disorders. Platelets are involved in 
pathophysiology of central nervous system diseases, especially in the pathogenesis of multiple sclerosis, but their role appears to be 
neglected. Platelets contribute to the inflammation and cooperate with immune cells in inflammatory and immune responses. These 
blood cells were identified in inflamed spinal cord and in the brain in chronic active lesions of multiple sclerosis and in the related animal 
models referred as Experimental Autoimmune Encephalomyelitis. This review summarizes recent insights in the platelet activation 
accompanied by the exocytosis of bioactive compounds stored in granules, formation of platelet microparticles, expression of specific 
membrane receptors, synthesis of numerous biomediators, generation of free radicals, and introduces the mechanisms by which 
activated platelets may be involved in the pathophysiology of multiple sclerosis. Understanding the role of platelets in multiple sclerosis 
may be essential for improved therapies.
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INTRODUCTION
Platelets have been recognized as the smallest 
blood cells that fulfill a complex role in hemostasis and 
thrombosis. Knowledge regarding the role of platelets 
in the development and severity of various disorders of 
central nervous system beyond thrombosis continues 
to emerge, but the role of platelets in multiple sclerosis 
appears to be neglected. There is a link between platelets 
and pathophysiology of multiple sclerosis (MS), and 
platelets may be key players in this disease (Starossom 
et al. 2015, Morel et al. 2015, 2016, Marcos‑Ramiro et al. 
2014, Sáenz‑Cuesta et al. 2014). Understanding the role of 
platelets in MS seems to be essential for improved therapy. 
MS is a chronic, demyelinating immune‑mediated 
disease of the central nervous system with axonal 
degeneration and astrogliosis (Kawahi et al. 2016). It 
is considered as a complex neurological disease with 
a variable clinical course and several pathophysiological 
mechanisms, such as axonal/neuronal damage, 
inflammation, demyelination, gliosis, remyelination and 
repair mechanisms (Miller 2012). In pathomechanisms of 
MS, the alterations of the immune system together with 
biochemical disturbances and disruption of blood‑brain 
barrier (BBB), are involved. Such processes are not 
uniformly represented in patients’ population, but may 
selectively predominate in individuals (Lehmann et al. 
2015). Activation and infiltration of mononuclear cells, 
mainly Ag‑specific CD4 and CD8 T cells in central nervous 
system and their reactivation by resident Ag‑presenting 
brain‑spinal cord glial cells are characteristic for the 
pathogenesis of MS. Activated T cells and brain glial 
cells secrete proinflammatory cytokines/chemokines 
along with generation of inflammatory mediators 
– highly reactive free radicals that leads to axonal 
loss (Jones et al. 2016). This autoimmune disease has 
a unknown precise etiology, however epidemiological 
data indicate multifactorial interactions between 
genetic susceptibility and environmental factors 
(Goodin 2016). MS affecting about 2.3 million people of 
the population in high‑prevalence areas, and it is one 
of the most common causes of neurological disability 
of young adults (Brola et al. 2016). There are three 
main types of MS, defined as: relapsing‑remitting (RR), 
secondary progressive (SP), primary progressive (PP) 
with a progressive‑relapsing (PR) subtype (Ayache et al. 
2016). The neuroaxonal degeneration is dominated in 
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both progressive forms – PPMS and SPMS, and correlate 
with brain disability and spinal cord atrophy (Seizer and 
May 2013). In SPMS, the central nervous system (CNS) 
atrophy is characteristic. It is generally very difficult 
to predict the clinical course of MS. Progression of 
disability seems to be increased in patients with higher 
number of relapses during the first and second year of 
the disease (Seizer and May 2013).
BLOOD PLATELETS
Blood platelets are anucleate cells that serve 
a critical function in hemostasis. In human body about 
1×1011 platelets are formed every day as the result of 
complex processes of differentiation, maturation and 
fragmentation of megakaryocytes (Xu et al. 2016b). 
Individual platelets vary in terms of volume, density and 
reactivity (Jones 2016). The normal platelet counts is in 
the range of 150–400×109/L. Under normal conditions 
platelets circulate in blood stream for 8–10 days and upon 
vascular injury, platelets instantly adhere to the exposed 
extracellular matrix resulting in platelet activation to 
form hemostatic plug. When platelet number is low, the 
risk of bleeding is high. 
Hemostatic activity of blood platelets
The primary biological function of platelets is to 
form hemostatic thrombi that prevents blood loss and 
maintains vascular integrity (Xu et al. 2016a). Platelets in 
the circulation are in resting state and become activated 
at sites of vascular injury by adhesion to adhesive proteins 
such as von Willebrand factor (vWf) and collagen, or 
by soluble platelets agonists such as thrombin, ADP, 
or thromboxaneA2 formed from arachidonic acid 
in stimulated platelets. The expression of multiple 
membrane receptors, both constitutive and activation 
dependent mediates platelet adhesion and aggregation 
at sites of vascular injury. Numerous platelet agonists 
induce signal transduction via their respective receptors 
and intermediate signaling events that stimulate platelet 
shape, secretory process, activation of integrin αIIbβ3. 
Binding of fibrinogen or other ligands to integrin αIIbβ3 
mediates platelet aggregation. Platelet activation is 
a dynamic process and involves multiple feedback loops 
and cross talk between different pathways in the cell. The 
most abundant integrin in platelets αIIbβ3 is normally 
in resting state, but is transformed into activated state 
after platelet activation. Binding of fibrinogen, vWf and 
some matrix proteins containing RGD sequences mediates 
stable platelet adhesion, aggregation and thrombus 
formation (Xu et al. 2016a). During activation of platelets 
microparticles (MPs) are released and are regard as 
a markers of platelet activation. Platelet MPs are the most 
abundant MPs found in the circulation (Badimon et al. 
2016, Ponomareva et al. 2016, Papapanagiotou et al. 2016, 
Boilard et al. 2015, Varon et al. 2015), and are potential 
mediators of blood coagulation by serving as circulating 
sources of tissue factor (TF) that is a transmembrane 
protein involved in thrombin generation. On the surface 
of MPs some quantity of phospatidylserine – a negatively 
charged aminophospholipid is exposed. Mechanisms 
of interaction of MPs with effector cells may involve 
a membrane fusion, endocytosis, or interaction of MPs 
with membrane receptor to stimulate cellular signaling 
events (Varon et al. 2015).
The most important adhesion molecules on platelets 
are integrins, heterodimeric transmembrane proteins that 
mediate interactions with extracellular matrix molecules 
and other adhesion molecules on the blood cells. They 
also play an important role in platelet signaling. Besides 
integrin αIIbβ3 (GPIIb/IIIa) platelets express beta 1 and 
beta 3 integrins such as α5β1 (VLA‑5), α6β1 (VLA‑6), α2β1 
(GPIa/IIa, VLA‑2) (Bender et al. 2016). Platelets possess 
a number of Ig superfamily of cellular adhesion molecules: 
ICAM‑2 (intercellular adhesion molecule‑2), JAM‑A, JAM‑C 
(junctional adhesion molecule) and PECAM‑1 (platelet 
endothelial cell adhesion molecule‑1). These molecules 
may interact with other cells. On the platelet membranes 
glycoprotein complex (GPIb‑V‑IX) is involved in the 
interaction of platelets with exposed subendothelium 
through binding to vWf. GPVI mediates platelet binding 
to collagen. Platelets express complement receptors, 
receptors for immunoglobins (FcR) and Toll‑like receptors 
(Lam et al. 2015).
Platelet secretory process
Platelet activation leads to exocytosis of granule 
constituents, release of stored and newly synthesized 
mediators. The discharge of membrane‑bound 
transcellular signaling molecules are also observed. 
Platelets are replete with secretory granules, which are 
critical to normal platelet function (Lam et al. 2015). 
There are three types of platelet secretory granules; dense 
granules, lysosomes and the most abundant α‑granules 
(Fig. 1). There are approximately 50–80 α‑granules per 
platelet. The α‑granules are essential to normal platelet 
activity, are formed in megakaryocytes and distributed 
to platelets during megakaryopoiesis. Their contents 
are released from platelets in order to achieve their 
physiological function. Granule membranes fuse with 
surface‑connected membranes of open canalicular system 
or the plasma membrane with expression of P‑selectin on 
the platelet surface. The α‑granules function depends on 
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their content. Proteomic studies suggest that hundreds of 
soluble proteins are released by these granules. Platelets 
secrete many mediators of blood coagulation that 
contribute to both primary and secondary hemostasis: 
fibrinogen, vWf, receptor complex GPIba‑V‑IX, the major 
receptor for fibrinogen, e.g. integrin αIIbβ3, collagen 
receptor GP VI, coagulation factors: V, XI and XIII. From 
α‑granules derives prothrombin – precursor of thrombin, 
high molecular weight kininogen, TF. The α‑granules 
release also inhibitory proteases: PAI‑1 (plasminogen 
activator inhibitor) and α2‑antiplasmin, antithrombin, 
tissue factor pathway inhibitor (TFPI), protein S, 
protease nexin‑2 (amyloid BA4 protein), plasminogen 
and protease plasmin contributing in fibrynolysis. These 
released proteins with pro‑ and anticoagulants properties 
contribute to regulation of coagulation. Until now it is 
Fig. 1. Main compounds of platelets secretory granules.
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not clear how compounds are segregated among granules 
and it is necessary to establish whether or not different 
α‑granule subpopulations exist in platelets. It is still not 
clear how these granules are organized within platelets 
and contribute to the multitude of physiological activities 
in which platelets function (Lam et al. 2015).
Platelet proteins involved in hemostasis and 
inflammation
Blood platelets have been long recognized as the cells 
that fulfill a complex role in hemostasis and thrombosis. 
Increasing evidence indicates that platelets contribute to 
diverse processes that extend beyond hemostasis. Recent 
discoveries confirm that during platelet activation the 
protein synthesis occurred. In spite of lack of transcription 
platelets possess stable mRNA transcripts with a long life 
correlated with platelet life span and show expression of 
two important key regulators of translation ELF‑4e and 
ELF‑2a. They have a variety of miRNA molecules responsible 
for translational regulation. Platelets synthesize several 
proteins involved in hemostasis including as integrins 
αIIbβ3, tissue factor, PAI‑1, cyclooxygenase (COX), Factor 
XI, protein C inhibitor and in inflammation (CCL5/
RANTES, IL‑1B). Stimulated platelets express either new 
proteins or additional amounts of constitutive proteins. 
In activated platelets the expression of Bcl‑3 and IL‑1β was 
demonstrated de novo (Bijak et al. 2013). Numerous studies 
have now revealed that anucleate platelets use a variety of 
mechanisms to translate mRNA into protein. In platelets 
constitutively are synthesized actin, glycoproteins 
GPIIb/IIIa, P‑selectin (Lam et al. 2015). Our current 
understanding of protein degradation pathways is less 
clear. Platelets express mRNAs for genes known to be part of 
the ubiquitin‑proteasome pathway. It is clear that platelets 
possess various proteases and at least two main protein 
degradation pathways: proteasome for degradation of 
ubiquitinated proteins, and calpain‑dependent degradation 
pathway (Kraemer et al. 2013). Calpain existing in two 
isoforms is calcium‑dependent cysteine protease, that 
displays widespread proteolytic activity. Calpain activation 
in platelets regulates both, the release of constituents 
from platelet α‑granules and cell spreading. Calpain plays 
a central role in cell death pathways. Blood platelets 
undergo apoptosis and many markers of apoptosis such 
as mitochondrial membrane depolarization, cytochrom 
c release and have been described. Calcium‑dependent 
activation of calpain cleaves a variety of intracellular 
proteins including Bcl‑x1 which is followed by translocation 
of proapoptotic bax and bak into mitochondria. Platelets 
express caspases that belong to – proteases involved in 
executing cell death. Activation of caspases is observed in 
response to thrombin, tumor necrosis factor alpha (TNFα), 
peroxynitrite. Caspases are responsible for the release 
of MPs from platelets. In platelets caspases 3, 8, and 9. 
involved in platelet apoptotic events are present (Mutlu et 
al. 2012). Aged platelets, which become activated during 
storage, have increased expression of pro‑apoptotic factors 
such as Bax and Bak. These two proteins are regulated 
by signal dependent mechanisms induced by a variety 
of agonists including thrombin and platelet activating 
factor (PAF). Resting platelets synthesize a number 
of constitutive proteins including thrombospondin, 
membrane glycoproteins (GPIb, IIb, IIIa), fibrinogen, 
albumin, vWf. Platelets contain NF‑κB – transcription 
factor that controls the gene expression of inflammatory 
mediators and can be involved in platelet function 
Table I. Platelets chemokines and their receptors
Platelet chemokine Common name Receptor(s) Platelet chemokine receptors
CXCL1 GRO‑α CXCR2>CXCR1 CCR1
CXCL4 PF4 CXCR3B, GAG CCR3
CXCL4L1 PF4alt unknown CCR4
CXCL5 ENA‑78 CXCR2 CXCR4
CXCL7 NAP‑2 CXCR2>CXCR1 CX3CR1
CXCL8 IL‑8 CXCR1, CXCR2
Those which are controversial  
are not shown
CXCL12 SDF‑1α CXCR4
CCL2 MCP‑1 CCR2
CCL3 MIP‑1α CCR1, 2, 3
CCL5 RANTES CCR1, 2, 3, 4, 5
CCL17 TARC CCR4, CCR8
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(Fuentes et al. 2016). Platelets synthesize and secrete 
a variety of matrix metalloproteinases (MMPs) including 
MMP‑1, MMP‑2, MMP‑3 and MMP‑14 (MT1‑MMP), and 
potentially MMP‑9 as well as the tissue inhibitors of 
metalloproteinases (TIMPs). MMPs are zinc‑dependent 
endopeptidases and together with the ADAM family 
(A Disintegrin And Metalloproteinase) belong to the family 
of metalloproteinases. They are synthesized and secreted 
as inactive proenzymes (Mastenbroek et al. 2015). Four 
endogenous tissue inhibitors of MMPs (TIMP‑1, TIMP‑2, 
TIMP‑3 and TIMP‑4) have been described in nucleated cells. 
In platelets and megakaryocytes, mRNA for TIMP‑1, TIMP‑2 
and TIMP‑3 have been identified (Seizer and May 2013). 
MMP‑1 in platelets is more abundant than other 
MMPs. Platelets exposure to collagen converts surfrace 
bound pro‑MMP‑1 to active MMP‑1 that in turn activates 
protease activated receptor 1 (PAR‑1) by cleaving the 
receptor and promotes platelet aggregation by PAR‑1. 
MMP‑2 after binding to GPIIb/GPIIIa on platelets, 
becomes converted to active MMP‑2 and can promote 
integrin‑mediated platelet aggregation. Moreover, CD40Ls 
shed from the platelet surface by active MMP‑2 may be 
a potent inducer of inflammatory processes in various 
CD40 expressing cells. Platelets can induce several MMPs 
in various cell types. Recently the so called Extracellular 
Matrix Metalloproteinase Inducer (EMMPRIN, CD147) 
has been identified on platelets (Zhu et al. 2014, Seizer 
and May 2013). It is an immunoglobin‑like receptor 
stored in α‑granules and released after thrombin or ADP 
stimulation. Interaction of platelets with monocytes 
induces EMMPRIN‑dependent monocyte production of 
NF‑κB‑mediated MMP‑9 and inflammatory cytokines such 
as IL‑6 and TNFα (Kral et al. 2016). The direct interaction 
of neutrophils and platelets seems to be mediated by 
neutrophilic PSGL‑1 and P‑selectin on activated platelets 
(Krishnamurthy et al. 2015).
Platelets contribution in inflammatory processes
Platelets by virtue of their immense number in the 
circulation, their numerous receptors, immunomodulatory 
mediators, cell adhesion molecules and platelet MPs (Lam 
et al. 2015) are able to participate in the inflammatory 
response (Koenen 2016). Bacterial endotoxins induce 
thrombocytopenia, hypotension, and sepsis. Blood 
platelet activation plays a critical role in LPS‑induced 
thrombocytopenia and tissue damage. Activated 
platelets produce ROS that cause damage of the vascular 
endothelium and promote multiple organ dysfunctions in 
sepsis (Casarin et al. 2011, Tyml 2011). Some studies showed 
that LPS stimulates platelet secretion of dense and alpha 
granules, and release of biological active inflammatory 
mediators (Zhang et al. 2009). Adhesion and aggregation of 
blood platelets is involved in pathogenesis of septic shock 
after damage of endothelial cells by LPS or inflammatory 
cytokines (Schrottmaier et al. 2016).
Circulating platelet‑leukocyte aggregates (PLAs) are 
the hallmark feature of sepsis and indicate that the close 
interaction between platelets and the immune system 
during inflammatory responses takes place (Thomas and 
Storey 2015). Adherent platelets rapidly express on their 
surfaces large quantities of P‑selectin and neutrophils can 
tether and roll via their PSGL‑1. This rolling is followed by 
firm adhesion of the neutrophil to adherent platelets via 
Mac‑1 binding to fibrinogen bound to platelet integrin 
GPIIb/IIIa or to GPIba (Wu et al. 2016). Recently, the ability 
of platelets to mediate adhesion of neutrophils has been 
presented by Langer and others (2012) in a mouse model of 
autoimmune encephalomyelitis (EAE). 
Platelets are one of the first cells to cumulate at 
an injured site, and local release of their compounds 
initiates an inflammatory cascade that attracts leukocytes, 
activates target cells and stimulates vessel repair and 
Table II. Platelets surface glycoproteins (GP’s) and its agonists
Classical CD #
Major platelet GP’s Receptors
INTEGRIN ACTIVATING LIGAND(S)
GP IIb/IIIa CD41b αIIbβ3 Fibrynogen vWF fibronectin vitronectin
GP Ib‑IX CD42a, b, c vWF thrombin
GP Ia‑IIa CD49b α2β1 Collagen
GP Ic‑IIa CD49e α5β1 Fibronectin
GP Ic‑IIa CD49f α6β1 Vitronectin, vWF fibronectin fibrinogen TSP
Vitronectin CD31 αVβ3 Laminin
PECAM‑1 CD31 Further interaction withendothelium
P‑selectin CD62P Interaction with leukocytes
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growth (Morrell et al. 2014). Thrombin and PAF generated 
at the inflammatory site stimulate platelet secretion 
within seconds to minutes (in vitro). Moreover, platelets can 
release many factors following heterotypical intercellular 
aggregation or adherence to leukocytes. Among the most 
potent inflammatory signaling molecules secreted by 
platelets are chemokines (Table I): RANTES (CCL5) binding 
inflamed endothelium, CXCL5, CCL3 and PF4 (CXCL4) 
(Raphael et al. 2015).
The mediators released from platelet granules, 
specially adhesive proteins, growth factors, chemokines 
important in hemostasis, may be implicated together with 
MMPs in the progression of inflammatory process (Morrell 
et al. 2014) and facilitates the involvement of platelets 
in acute chronic inflammatory diseases (Müller et al. 
2015). Moreover, the expression of various and numerous 
membrane receptors (Table II), both constitutive and 
activation‑dependent (P‑selectin, PSGL‑1, CD40, GPIb/
IX/V complex and integrin αIIbβ3) mediates platelet 
adhesion and aggregation involved not only in hemostasis 
and thrombosis, but also in inflammation (Lam et al. 
2015). Platelets express numerous adhesion molecules 
and ligands that facilitate the interaction of platelets with 
leukocytes and endothelium cells. Activated platelets 
express on their surfaces a large amount of P‑selectin 
derived from membrane α‑granules. P‑selectin can mediate 
adhesion to cells expressing PSGL‑1, primarily neutrophils, 
monocytes and other leukocytes, endothelial cells and 
other platelets. Platelets play a major role in acute and 
chronic inflammation. They release of proinflammatory 
mediators, MMPs, display of surface molecules that have 
inflammatory functions and interact with leukocytes and 
endothelium cells. Platelets have potent inflammatory 
activities and molecular mechanisms that link the 
hemostatic and inflammatory systems (Chatterjee and 
Geisler 2016, Morrell et al. 2014). A wide array of factors 
released from platelets regulate intercellular aggregation 
(homo‑ and heterotypical) chemotaxis, angiogenesis, 
matrix degradation and signaling pathways in target 
cells. Cell‑cell interactions provide critical mechanisms by 
which platelets link thrombosis, inflammation and related 
processes. These interactions include integrin–dependent 
platelet aggregation, rolling of leukocytes on adherent, 
activated platelets via P‑selectin/PSGL1 interactions and 
engagement of PSGL‑1 by P‑selectin mediated adhesion of 
platelets to leukocytes in the circulation. These molecular 
mechanisms are involved in physiological hemostasis and 
inflammation but also contribute to inflammatory diseases 
that include neurological disorders such as MS. In activated 
platelets are generated inflammatory lipid mediators such 
as eicosanoids (TXA2), in the pathways stimulated by COX 
or PAF which transmits outside‑in signals to different cell 
types involved in innate immune defense. PAF is a strong 
platelet activator, induces IL‑1β synthesis in platelets.
Platelets as mediators of the inflammation contribute 
to the inflammatory process by expressing receptors 
that facilitate adhesion of platelets with other cells and 
by releasing chemokines. P‑selectin translocated from 
granules to the platelet surface membrane during activation 
interacts with endothelial cells, monocytes, neutrophils and 
lymphocytes. P‑selectin mediates interaction of platelets 
with PSGL‑1 (P‑selectin glycoprotein‑1) expressing on 
immune cells (Thomas and Storey 2015). Moreover, 
platelets exert influence on inflammation by release 
of pro‑inflammatory and immune‑modulating factors. 
A wide range of chemokines including CXCL1, CXCL4, 
CXCL5 (ENA‑78, epithelial neutrophil‑activating protein 
78), CXCL7 (PBP, B‑TG, CTAP‑III, NAP‑2), CXCL8 (IL‑8), 
CXCL12, CCL2, CCL3 (MIP‑1α, macrophage inflammatory 
protein‑1α), CCL5 (RANTES) (Table I), are stored in platelet 
α‑granules (Raphael et al. 2015). Among these chemokines 
CXCL4 and CXCL7 are the abundant. The most abundant 
platelet chemokine CXCL7 can be cleaved to generate four 
distinct chemokines such as platelet basic protein (PBP), 
CTAP‑III, β‑thromboglobulin and NAP‑2 with significant 
chemotactic activity. Platelet α‑granules contain different 
proangiogenic and antiangiogenic proteins (angiopoietin, 
CXCL12 and MMPs (MMP‑1, ‑2, and 9). There are numerous 
growth factors such as PDGF, FGF,VEGF, EGF, HGF, IGF 
released from α‑granules. Platelets are the main source of 
CD40L (CD154). CD40L is a type II membrane glycoprotein 
of TNF family found on T cells, B cells and platelets. Soluble 
form (sCD40L) is released from activated platelets and 
platelets release approximately 95% of all sCD40L found 
in plasma (Saluk‑Juszczak and Królewska 2010). Excess 
sCD40L contributes to BBB permeability and is thought to 
regulate permeability in the inflammatory disorders of the 
CNS (Davidson et al. 2012). PSGL‑1, implicating platelets 
and can induce maturation and activation of dendritic cells.
THE POTENTIAL ROLE OF BLOOD 
PLATELETS IN MULTIPLE SCLEROSIS
Multiple sclerosis is a heterogenous disease of 
central nervous system with complex pathogenesis that 
involves autoimmune, inflammatory, neurodegeneration 
and demyelination processes. In MS the immune cells 
of the body attack the myelin sheats surrounding and 
protecting neurons in the CNS. Moreover, oxidative stress 
in MS is associated with significant damage to myelin 
and axons which in turn leads to clinical symptoms. The 
studies of Han and others (2008) by proteomic analysis 
of active multiple sclerosis lesions revealed the presence 
of proteins involved in the coagulation cascade (Han et 
al. 2008). The proteins such as tissue factor and protein 
C inhibitor were identified within chronic active plaque 
samples. It indicates that the coagulation cascade is 
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implicated in pathological stages of MS. There is a wide 
range of clinical symptoms in MS different at early 
and progressive stage. The early phase of this disease 
is characterized by immune‑mediated responses with 
microgial activation and cellular infiltration connected 
mainly with inflammation of white matter and leading 
in progressive phase to the demeylination and axonal 
destruction. Inflammation and oxidative stress within the 
CNS are major causes of ongoing damages and evidences 
suggest that in the mechanisms of tissue damage in MS 
oxidative/nitrative stress is involved (Miller et al. 2012).
There is a probable link between platelets and 
pathophysiology of other neurodegenerative diseases 
(such as Alzheimer,s disease, Parkinsons disease, 
Huntingtons disease or Multiple Sclerosis) (Bronstein 
et al. 2015). There are numerous mechanisms by which 
platelets could contribute to pathophysiology of MS. 
The possible involvement of platelets in MS was first 
investigated by Putnam in 1937 (Putnam 1937). In the 
1950–1960s several studies (Nathanson and Savitsky 
1952, Wright et al. 1965) were focused on the relations 
of platelets to CNS demyelination and reported 
increased platelet adhesiveness correlated with activity 
of MS (Morel et al. 2015, 2016) (such as fibrin, tissue 
factor, protein C) in lesion of MS patients suggests 
procoagulant state (Han et al. 2008). Abnormalities of 
platelet reactivity in MS patients and chronic platelet 
activation in MS seem to be well established (Morel et 
al. 2015, 2016). Sheremata and others (2008) reported 
increased platelet activation assessed by the elevated 
levels of platelet activation markers such as platelet MPs 
and P‑selectin on platelet membranes in MS patients.
Since MS is mediated via migration of leukocytes and 
monocytes from the peripheral circulation to CNS, one of 
the important mechanisms, how platelets may modulate 
inflammation is their interaction with leukocytes 
and the release of bioactive mediators, mainly matrix 
metalloproteinases and different chemokines (especially 
PF4) (Starossom et al. 2015). Platelets may be a key source 
of IL‑1α that may activate of brain endothelium and enable 
the entry of white blood cells and drives to cerebrovascular 
inflammation (Thornton et al. 2010). Cerebrovascular 
inflammation is a major contributor to diverse forms 
of brain injury in MS, and among peripheral circulating 
cells that play a critical role in cerebral inflammation are 
platelets, the smallest blood cells. They are the one of the 
first cell types to arrive at the site of vascular dysfunction 
and can induce cerebrovascular inflammation (Rainger et al. 
2015). MS is a devastating neuro‑inflammatory disease with 
an autoimmune reaction triggering the disease. Recently, 
Langer and others (2012) studied the role of platelets 
in mediating CNS inflammation in EAE – experimental 
autoimmune encephalomyelitis corresponding to MS. In 
the rodent model of MS, animals were immunized with 
antigens derived from the myelin sheath such as myelin 
oligodendrocyte glycoprotein or myelin basic protein. It 
lead to infiltration of autoimmune T cells into the brain 
and spinal cord. The autoimmune reaction induces the 
recruitment of neutrophils, monocytes and macrophages 
(inflammatory cells) and the pro‑inflammatory stimulation 
of microglia cells leading to destruction of the myelin 
sheath, that precipitates demyelinating lesions. Platelets 
were abundant in the inflamed brain and spinal cord of 
mice subjected to the EAE model. The data presented 
by Langer and colleagues (2012) suggest that platelets 
contribute rather to the inflammatory phase of EAE than 
to the immunization phase of EAE.
Under physiological conditions the BBB is tight and 
prevents penetration and adhesion of inflammatory cells. 
In MS, upon inflammatory stimulation the BBB itself and 
its anti‑inflammatory function are compromised changed 
(Wevers and de Vries 2016). It enables the inflammatory 
cells (T cells, monocytes/macrophages) penetrate the BBB. 
Microglia cells such as resident inflammatory cells are 
activated. Due to neuroinflammation disruption of the BBB, 
platelets rapidly adhere to the endothelium cells, became 
activated and contribute to neurovascular inflammation 
caused by multiple interactions with endothelial and 
inflammatory cell (Lawrence et al. 2010). PAF is probably 
involved in the disruption of endothelial functions and 
could be responsible for the early disruption of the BBB in 
MS, since elevation of PAF in the CSF and plasma of RRMS 
patients was reported (Starossom et al. 2015). P‑selectin 
is consider to be marker of RRMS compared to secondary 
progressive MS. Excess of sCD40L derived from platelets 
contributes to BBB permeability (Davidson et al. 2012). 
Platelet interaction with leukocytes at the endothelium of 
the BBB may be responsible for the release of the PECAM‑1 
to the circulation and associated infiltration of leukocytes 
(Jones et al. 2016). Metalloproteinases derived from 
platelets are also the participants in disruption of the BBB 
in MS (Brkic et al. 2015).
Platelets present in the inflamed neuronal tissue may 
contribute to neurovascular inflammation and neuronal 
disease in several ways (Horstman et al. 2010, Langer et al. 
2012, Steinman 2012, Vogel et al. 2013). They can adhere 
to endothelium and propagate inflammation via several 
mechanisms such as recruitment/activation of leukocytes 
or activation of microglia cells; activated platelets release 
pro‑inflammatory mediators (chemokines, cytokines). On 
inflammatory stimulation platelets rapidly adhere to the 
endothelium or to the subendothelial extracellular matrix 
at sites of vascular endothelial injury (Lam et al. 2015). 
Several receptors on platelet surface such as glycoprotein 
VI, integrin αIIbβ3, integrin CD41/CD61, GPIb/IX/V 
complex mediate platelet adhesion and aggregation. 
The direct interaction of platelets with endothelial and 
inflammatory cells promote leukocyte recruitment to the 
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inflamed tissue and various platelet receptors are involved 
in these processes: P‑selectin of activated platelets and 
GPIb (component of the GPIb/GPIX/GPV complex) that is 
responsible for binding of von Willebrand factor. Receptor 
GPIb also interacts with the leukocyte integrin Mac‑1 
promoting the interactions of platelets and leukocytes. 
On activated platelets interactions of leukocytes with 
platelets include the binding of P‑selectin glycoprotein 
ligand‑1 (PSGL‑1) on leukocytes to platelet P‑selectin 
(Rainger et al. 2015). Recently, Sotnikov and others (2013) 
showed a new role of platelets which directly recognize 
a neuronal damage and communicate with the cells of 
the immune system in the pathogenesis of MS. Platelets 
recognize specific glycolipid structure in brain, respond to 
neurovascular damage and promote neuroinflammation. 
The study of Sotnikov and others (2013) revealed that 
platelets recognize the sialated gangliosides in the lipid 
rafts on the surface of astrogial and neuronal cells that are 
important for the development of the EAE in an animal 
model for MS. Gangliosides are present in many tissues, but 
the most abundant source is the brain. Among numerous 
gangliosides only gangliosides GT1b and GQ1b were 
specifically recognized by the platelets (Sotnikov et al. 
2013). The recognition of these sialated glycosphingolipids 
by platelets involved multiple receptors with P‑selectin 
playing the central role. Platelets penetrate the BBB, may 
recognize sialated gangliosides within the lipid rafts and 
accumulate in the lipid rafts‑rich areas in the model of 
neuroinflammation. Sotnikov and others (2013) examined 
the platelet reaction to the brain lipid rafts in the EAE model 
and observed the platelet secretory process in the CNS 
during EAE by measuring the levels of released of CD41+ 
and PF4/CXCL4. Moreover, they observed that mice with 
EAE had 25‑fold higher level of PF4 in serum compared to 
the healthy mice, and similar to the brain lipid rafts treated 
mice. It indicates that during neuroinflammation platelets 
interact with brain lipid rafts and are highly sensitive to 
the activation and degranulation in the periphery. The 
obtained data suggest that platelet‑lipid rafts interaction 
could play an important role in EAE, and could be involved 
in the activation of cells of immune system both in the 
periphery and in the CNS. The study reveals the lipid rafts 
(stable dense areas of the membrane) of astrocytes and 
neurons as new ligands within the CNS that are recognized 
by platelets and could play an important role in a neuronal 
damage in the induction and perpetuation of inflammation 
in the CNS. The role of various platelet‑derived bioactive 
lipids in MS is not yet clear. In inflammatory process are 
involved not only platelet prostaglandins but other lipids 
such as resolvins generated via lipoxygenase pathway 
(Moro et al. 2016), PAF (Edwards and Constantinescu 2009), 
and endocannabinoids released from activated platelets 
(anandamid and 2‑arachidonoylglycerol) (Hind et al. 2015). 
Moreover, platelets express endocannabinoid receptors CB1 
and CB2 (Brantl et al. 2013). Increased platelet activation 
could lead even to the changes of endocannabinoid level in 
brain (Brantl et al. 2013).
Platelets produce approximately 95% of all sCD40L 
found in plasma, which is released upon activation and 
excess soluble CD40L contributes to BBB permeability 
when increased infiltration of the CNS by leucocytes and 
platelets occurs (Davidson et al. 2012). Moreover, CD40Ls 
shed from the platelet surface by active platelet MMP‑2 may 
be a potent inducer of inflammatory processes in various 
CD40 expressing cells (Saluk‑Juszczak and Królewska 2010).
MS patients displayed higher levels of platelet activation 
markers in their peripheral blood and plasma. The levels of 
platelet MPs, platelet aggregates and P‑selectin, markers 
of platelet activation measured by flow cytometry method 
were increased (Sheremata et al. 2008). It indicates that 
platelets are chronically activated in MS patients. Data 
described by Habets and colleagues (2013) confirmed that 
adhesion of platelets from MS patients are augmented and 
aggregation is also increased. In platelets from patients 
with relapsing‑remitting form of MS the increased 
aggregation was not observed, but activities of the 
enzymes that hydrolyze adenine nucleotides in platelets 
were decreased (Spanevello et al. 2010). It may suggest that 
enzymes ectonucleotidases contribute to the alteration of 
platelet function in MS (Spanevello et al. 2010).
REACTIVE OXYGEN SPECIES  
AND REACTIVE NITROGEN SPECIES  
IN MULTIPLE SCLEROSIS
Reactive Oxygen Species and Reactive Nitrogen Species 
(ROS, RNS) are generated in brain in large amounts as part 
of cellular physiology. A failure of antioxidant mechanisms 
or overproduction of ROS may cause damage to proteins, 
lipids and nucleic acids, leading even to cell death. There 
are defense mechanisms against the oxidative/nitrative 
stress. CNS is particularly vulnerable to oxidative damage 
due to cellular features of CNS and predisposing to 
oxidative damage within the oligodendrocyte population 
(Kim et al. 2015). CNS is characterized by low levels of 
antioxidant defenses, membrane rich in polyunsaturated 
fatty acids, high iron content and a high demand for 
oxygen. Moreover, the composition of myelin seems to be 
a preferential target of ROS (Alizadeh et al. 2015) since it 
contains high protein: lipid ratio. Reduction in oxidative 
damage seems to be an important therapeutic strategy to 
slow or stop disease processes in MS. Many drugs in clinical 
practice or currently in trial target this mechanism. Stem 
cells, specifically mesenchymal stem cells (MSCs) therapies 
could offer an alternative source of antioxidant capability 
(DeSantiago et al. 2013).
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In the CNS nitric oxide (NO) produced in response to 
inflammation mainly through the induced NO synthase 
(iNOS) (Förstermann and Sessa 2012) plays a role in the 
immunopathogenesis of MS (Miljković and Spasojević 
2013). In the CNS of animals with EAE the increase of NO 
production was observed (D’Souza et al. 2016).
Evidence suggests that inflammatory process 
and oxidative stress within CNS are major causes of 
ongoing tissue damage and demyelination (Desai et al. 
2016, Förstermann and Sessa 2012) in the MS patients. 
Demyelination and axonal destruction, that are the 
pathological hallmarks of MS are caused by ROS and 
RNS generated by invading inflammatory cells as well 
as resident CNS cells. ROS initiate lesion formation by 
inducing the BBB disruption, enhance leukocyte migration 
and myelin phagocytosis. ROS by inducing cellular damage 
to essential biological structures of vulnerable CNS cells 
contribute to lesions persistence (Beckhauser et al. 2016). 
The presence of extensive damage to lipids, proteins and 
nucleotides occurring in the active demyelinating MS 
lesions, predominantly in reactive astrocytes and myelin 
laden macrophages was presented by van Horssen and 
colleagues (2008). The authors showed that in active 
demyelinating MS lesions compared to normal‑appearing 
white matter and white matter tissue antioxidant 
enzymes (superoxide dismutase (SOD), catalase and heme 
oxygenase‑1) are markedly upregulated, especially in 
hypertrophic astrocytes and myelin‑laden macrophages. 
They suggest that this increase of antioxidant enzyme 
production in inflammatory MS lesions might reflect an 
adaptive defense mechanism against ROS‑induced damage 
(van Horssen et al. 2008). Blood platelets by the production 
of ROS (Morel et al. 2016) may be involved in the damage of 
CNS in MS patients. The levels of ROS and RNS can increase 
dramatically under condition such as inflammation. This 
increase can overwhelm the inherent antioxidant defense 
within lesions and lead to oxidative/nitrative stress and 
damage of different cellular structures and potentially cell 
death. Oligodendrocytes are more sensitive to oxidative/
nitrative stress in vitro than astrocytes and microglia, 
probably due to a decreased antioxidant defense. And 
therefore it might lead in vivo to selective oligodendrocyte 
death, and thereby demyelination. The reactive species 
may also damage of the myelin sheath, promoting the 
attack by macrophages. Evidence for the existence of 
oxidative stress within inflammatory demyelinating 
lesions includes the presence of oxidative/nitrative 
stress markers such as lipid and protein peroxides and 
nitrotyrosine. ROS and RNS are produced as part of the 
inflammatory response and have a potential role in 
tissue damage in MS. Activated platelets as an additional 
source of ROS/RNS could be involved in this process. High 
levels of superoxide anion, NO and peroxynitrite have 
been demonstrated in spinal fluid from patients with 
MS (Calabrese et al. 2002) and NO in spinal cord of mice 
with EAE (Dasgupta et al. 2013). Redox modulation by 
S‑nitrosylation contributes to neuronal synaptic damage 
in neurodegenerative diseases (Nakamura and Lipton 
2011). Pathological changes noted in post‑mortem or biopsy 
tissue from MS patients revealed some of the mechanisms 
of tissue damage, some of them specifically relating to 
oxidative damage (Witherick et al. 2011).
Activation of platelets is important for their function 
in both, physiological and pathological processes. It is well 
known that stimulated platelets produce ROS and RNS 
that can be involved in regulation of platelet activation 
(Chen et al. 2013). ROS generated by activated platelets 
induce the changes in intracellular Ca ions and behaves 
as second messengers in thrombin and collagen activated 
platelets. After platelet stimulation the formation 
of platelet aggregates is associated with the burst of 
hydrogen peroxide, which in turn induces the platelet 
aggregation mediated by binding of fibrinogen to integrin 
receptors (GPIIb/IIa) independent on ADP secreted from 
dense granules and enhances aggregation induced by 
arachidonic acid. Intracellular source of ROS is arachidonic 
pathways via COX or 12‑lipoxygenase (12‑LOX), metabolism 
of phosphoinositides, the glutathione cycle. ROS are 
generated mostly by activation of NADPH oxidase and 
xantine oxidase. ROS may modulate the signal transduction, 
or regulate platelet function by reducing NO bioavailability, 
since ROS scavenge platelet or endothelium derived NO. 
Rapid reaction of NO and superoxide anion produces toxic 
peroxynitrite which is a potent nitrating and oxidizing 
agent and can modify structure and function of different 
biomolecules. In stimulated platelets iNOS expression 
is increased. On the other hand, platelets represent 
a relevant target for the action of exogenous ROS derived 
from vascular wall and under inflammatory conditions are 
also exposed to phagocyte dependent production of high 
quantities of ROS (Chen et al. 2013). Activated platelets in 
CNS may be an additional source of reactive oxygen and 
nitrogen species leading to oxidative stress that is also 
responsible for tissue damage and demyelination observed 
in MS. Platelets seem to be important perpetrators of 
MS pathology and targeting these cells might be a novel 
therapeutic approach to consider (Langer et al. 2012, 
Steinman 2012).
CONCLUSIONS
Platelets are one of the most important elements of 
human blood, derived from the megakaryocytes in the 
bone marrow. Blood platelets are multifunctional and 
what is more, they are two‑faced. They play a central 
role in hemostasis and thrombosis, clot retraction, 
vessel constriction and repair. Thanks to their shape 
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and small size, platelets take part in initial stages of the 
blood coagulation processes resulting in the arrest of 
bleeding sites of vascular injury. In this way they stop 
blood loss. 
Apart from their well‑recognized role in hemostasis, 
there is increasing recognition of the importance of 
platelets during inflammatory processes and platelets are 
a major source of pro‑innflamatory molecules (P‑selectin, 
tissue factor, CD40L, metalloproteinases). 
Platelets are important for the innate and adaptive 
immune response and combat infection: viruses, bacteria 
and microorganisms.
Activated platelets and MPs are crucial in propagation 
of major diseases like CNS diseases (MS, Alzheimer), 
atherosclerosis, rheumatoid arthritis, cancer and tumor 
growth. Upon activation, platelets change their shape from 
a smooth, rippled surface to spherical with the extrusion 
of the pseudopods and release the contents of their 
α‑granules, secreting a variety of cytokines, chemokines 
and growth factors. Membrane budding gives rise to MPs, 
another biologically active participant within the blood 
stream. They are also capable of post‑transcriptional 
modification of mRNA, which was packaged during platelet 
formation from megakaryocytes. Such process shows that 
platelets are capable of producing over 1100 proteins as 
identified by proteomics. 
What is more, blood platelets have been regarded as 
biomarkers of neurological diseases, including MS. There 
is a coexisting between platelets and this demyelinating, 
inflammatory, autoimmune disease. There are numerous 
mechanisms by which platelets might be involve in the 
pathophysiology of MS. The presence of platelet specific 
glycoproteins – GPIIb/IIIa and also several coagulation 
proteins – fibrin, tissue factor, protein C, in lesion of MS 
patients suggests procoagulant state. In patients with MS, 
abnormalities of platelet reactivity and chronic platelet 
activation, are observed. Sheremata and others (2008) 
have shown that platelets are significantly activated in 
MS patients assessed by the elevated levels of MPs and 
P‑selectine on platelet membranes – an platelet activation 
markers. Moreover, platelet activation might be an 
epiphenomenon consequent to the disease process in MS, 
probably secondary to endothelial injury. Sheremata and 
others (2008) have reported elevated plasma endothelial 
microparticles (EMP) in MS, positive for platelet 
endothelial cell adhesion molecule‑1 (CD31/PECAM‑1). 
The authors suggested that this increase in EMP can reflect 
the interaction of activated T‑cells with endothelium. The 
interaction of released PMP with underlying endothelium 
contributes to the endothelial abnormalities involved 
in the pathophysiology of MS has been also possible. It 
is known that variety of bioactive agents including PAF, 
amyloid precursor protein, complement factors and other 
molecules could be transported by the PMP, all of which 
might contribute to the disease process in some manner. 
Although researches of the role of cell‑derived MPs in 
disease processes are still in its infancy, it is reasonable 
to postulate that PMP may play an active role in the 
pathogenesis of MS.
In others studies, Nathanson and Savitsky (1952) 
have proved the association between increased platelet 
adhesiveness with MS, what correlates with disease 
activity. Lindberg and colleagues (2004) based on 
microarray analysis of chronic human MS lesions, they 
revealed upregulation of the platelet‑specific GPIIb 
receptor. In their studies, platelets were indentified in 
inflamed spinal cord and also in brain of experimental 
autoimmune EAE mice. The authors demonstrated 
that by targeting the platelets‑specific receptor GPIbα, 
the disease severity is reduced. Platelets in lesions of 
human MS patients were identified in the same manner. 
Furthermore, they described the correlation between EAE 
symptoms and levels of PAF. Their discovery is consistent 
with the observation of increasing PAF levels in CSF of 
relapsing MS patients. Kim and others (2015) have shown 
that the brain inflamation has been modulated by the 
platelet‑derived serotonin through promoting neutrophil 
recruitment. Likewise, SERT knockout mice displayed 
increased levels of circulating 5‑hydroxytryptamine 
(5‑HT) and attenuated symptoms of EAE. What is more, 
the number of newly formed lesions in patients with 
relapsing MS had been reduced by the selective serotonin 
reuptake inhibitors, which were served patients with 
relapsing MS.
Langer and others (2012) have described a key role for 
platelets in the pathogenesis of demeylinating disease. 
They observed that platelets are present in chronic 
active lesions of MS. An early of MS lesions using gene 
microarrays indicated that glycoprotein IIb/IIIa was 
highly expressed in MS lesions and particularly in the 
more chronic stages of the disease. There is evidence that 
platelets themselves are highly activated in some patients 
suffering for MS, again emphasizing that modulating 
platelet activity may be beneficial. 
It is well known that blood platelets contain at least 
300 proteins, some of them take part in regulating 
inflammation, and after platelet activation the numerous 
immunomodulatory mediators have been released, 
such as: RANTES, IL‑1β, PF4, PAF (Li et al. 2011). It is 
believed that blood platelets participate in one of the 
most common pathological process of MS – initiation 
of immune‑mediated cascade in the peripheral immune 
system and targeting CNS myelin (Palmer 2013). The 
therapeutic approaches in MS are mainly aimed at down 
regulation of the multifarious elements of the immune 
system, which are involved in this immunological 
cascade. Since 1993 when interferon therapy has been 
introduced, a major step has been taken in the field of 
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MS immunotheraphy. Over the years, the more effective 
and specific immunoactive drugs have been discovered 
and approved for the treatment of MS (i.e. alemtuzumab, 
azathioprine, dimethyl fumarate, fingolimod, glatiramer 
acetate, mitoxantrone, natalizumab and teriflunomide). 
During the last five years the orally administered 
medications have been approved, such as: fingolimod, 
teriflunomide and dimethyl fumarate, also monoclonal 
antibody (alemtuzumab) and glatiramer acetate and 
a pegylated formulation of interferon beta 1a (Radick 
and Mehr 2015). It seems that the increased specificity of 
these new treatments in the course of MS is paralleled by 
greater efficacy. Unluckily, this new therapy on one side 
increases efficacy but on other side is associated with 
an increased risk of drug intolerance. Interferon beta 
1a as well as glatiramer acetate belong to the injectable 
modifying drugs and are used as a first‑line treatment in 
the course of MS. Glatiramer acetate is a synthetic polymer 
of amino acids that contains mixture of L‑glutamic acid, 
L‑lysine, L‑alanine and L‑tyrosine which is commonly 
used as a safe and effective drug. It is characterized by 
long‑term clinical efficacy with approximately 30% 
decrease in annual number of relapses (McGraw and 
Lublin 2013). Ponomareva and colleagues (2016), using 
flow cytometry method, have been proved that glatiramer 
acetate modulates platelet functioning by decreasing 
the level of their activation that leads to the increased 
bleeding time in vivo. Thus, authors suggested that blood 
platelets cannot be exposed to high concentration of 
glatiramer acetate (500 µg/ml) in order to decrease side 
effects of glatiramer acetate injections. It was also proved 
that interfern beta 1a reduces the level of blood platelets, 
which results in greater susceptibility of MS patients 
to bleeding and brusining (Ponomareva et al. 2016). 
Similarly fingolimod that is approved as a second‑line 
treatment in MS rapidly decreases the number of blood 
platelets. It is very promising oral drug modifying course 
of the MS which efficacy in reduction of the diseases 
relapses is about ~60% (Gasperini and Ruggieri 2012). 
Farrokhi and others (2015) suggested that fingolimod’s 
effectiveness may depend on its ability to reduce a level of 
blood platelets in MS patients. This supposition confirms 
that blood platelets may be involved in inflammation and 
neurodegeneration in MS.
The broadened treatment options enable a much more 
differentiated and also individualized therapy of MS. 
Also, implementation of the pharmacogenetics, which 
is related with individual response of the organism to 
the drugs, may constitute a promising search direction 
supporting MS treatment and can help to strengthen 
the efficacy of the drug before its use. It should be bear 
in mind that an evidence‑based data for therapeutic 
decision‑making which are relevant in clinical practise 
are not always available.
Generally available methods of MS therapy potentially 
contribute only to delay or prevent relapses from occurring, 
relieve their effects and limit their incidence. As yet, there 
is no effective, scientifically proven treatment method, 
which would slow down the progress of MS. Therefore, 
understanding platelet physiology in the pathobiological 
processes associated with venues in the inflamed brain 
might be a key for providing new targets for therapy in MS.
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